Lawrence Pasik, MD
Allergy & Immunology · West Bloomfield, MINPI 1922071562
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 175 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations.
Across 175 payments — averaging $20.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$619
- AstraZeneca$337
- CSL Behring$294
- GSK$273
- Pfizer$266
- Boehringer Ingelheim$245
- plus $2K from 26 others
Across 17 payments — averaging $4836.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- LEO Pharma AS$65K
- Hikma Pharmaceuticals USA$18K
What the payments were for
- Food & beverage$3,43997%
- Education$973%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 30 | $619 |
| AstraZeneca | 20 | $337 |
| CSL Behring | 12 | $294 |
| GSK | 17 | $273 |
| Pfizer | 14 | $266 |
| Boehringer Ingelheim | 13 | $245 |
| Novartis | 6 | $150 |
| Regeneron Healthcare Solutions, Inc. | 6 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $128 |
| Alk-abello, Inc | 7 | $123 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Amgen | 5 | $96 |
| Teva Pharmaceuticals USA, Inc. | 4 | $92 |
| Genentech USA, Inc. | 5 | $90 |
| Hikma Pharmaceuticals USA | 5 | $83 |
| Optinose US, Inc. | 4 | $74 |
| Pharming Healthcare, Inc. | 3 | $56 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $51 |
| Kaleo, Inc. | 2 | $39 |
| Ionis Pharmaceuticals, Inc. | 1 | $35 |
| Octapharma USA, Inc. | 1 | $34 |
| Biocryst US Sales Co., LLC | 1 | $32 |
| Grifols USA, LLC | 1 | $26 |
| Incyte Corporation | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Verona Pharma, Inc. | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Jubilant Hollisterstier LLC | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Covis Pharma GmbH | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
| AbbVie | 1 | $14 |
How this compares
$3,536 in reported general payments places this provider in the 55th percentile of 119 allergy & immunology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $49,754 |
| Spiriva RespimatTiotropium Bromide | 35 | $29,521 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 23 | $24,966 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $13,642 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $4,608 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,256 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $1,963 |
| Montelukast Sodium | 94 | $1,817 |
| Azelastine Hcl | 31 | $1,506 |
| Ipratropium Bromide | 19 | $1,296 |
| Fluticasone Propionate | 33 | $903 |
| Azithromycin | 109 | $770 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 36 | $438 |
| Doxycycline Hyclate | 24 | $259 |
| Fluconazole | 18 | $144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $273 | $63,39674 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $245 | $54,48758 claims |
| AstraZenecaSymbicort | $337 | $2,25611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 119 allergy & immunology providers in Michigan.
Other allergy & immunology in West Bloomfield
- Cathryn LuriaWest Bloomfield$5K
- Nena KasmikhaWest Bloomfield$5K
- Gagandeep CheemaWest Bloomfield$4K
- Steven StrykCanton$949K
- Hassan NasirWest Branch$736K
- Theodore KelbelGrand Rapids$695K
- Nicholas HartogGrand Rapids$575K
- Kathleen DassOak Park$446K
- Pulin PatelMount Clemens$431K
- Alan BaptistAnn Arbor$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.